Cardiovascular disease, statins and vitamin D

British Journal of Nursing

Volumn 21, Issue 4, 2012, Pages 214-220

  Wilding, Peter Mark ^a  

^a LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

25 hydroxy vitamin D; C reactive protein; HMG CoA reductase inhibitors; JUPITER trial; Myocardial infarction; Pleiotropy; Rosuvastatin; Statins; Stroke; Venous thromboembolism; Vitamin D

Indexed keywords

EID: 84858229388     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2012.21.4.214     Document Type: Article

References (51)

1. Abou-Saleh H, Yacoub D, Théorêt JF et al (2009) Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation 120(22): 2230-9
2. Ahmed W, Khan N, Glueck CJ et al (2009) Low serum 25 (OH) vitamin D levels (
3. Albert MA, Glynn RJ, Ridker PM (2003) Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107(3): 443-7 (Pubitemid 36158047)
4. Ballantyne CM, Raichlen JS, Nicholls SJ et al (2008) Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117(19): 2458-66 (Pubitemid 351670452)
5. Beer TM, Venner PM, Ryan CW et al (2006) High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 135(3): 392-4 (Pubitemid 44484849)
6. Bisoendial RJ, Kastelein JJ, Stroes ES (2007) C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 195(2): e10-e18 (Pubitemid 350087968)
7. British Heart Foundation Health Promotion Research Group, (2010). Coronary Heart Disease Statistics - 2010 Edition. Department of Public Health, University of Oxford, Oxford. Available from: http://www.bhforg.uk/idoc.ashx? docid=9ef69170-3 edf-4fbb-a202-a93955c1283d&version=-1 [Last accessed: May 27, 2011]
8. Buell JS, Dawson-Hughes B, Scott TM et al (2010) 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 74(1): 18-26
9. Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99(20): 13043-8
10. Department of Health (2000) Coronary Heart Disease: National Service Framework for Coronary Heart Disease - Modern Standards and Service Models. Department of Health, London
11. Department of Health (2010) Liberating the NHS. Department of Health, London
12. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM, (2010) Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 121(1): 143-50
13. Flynn PD, Byrne CD, Baglin TP, Weissberg PL, Bennett MR (1997) Thrombin generation by apoptotic vascular smooth muscle cells. Blood 89(12): 4378-84 (Pubitemid 27260247)
14. Food and Drug Administration (2010) Crestor - Rosuvastatin Calcium. Food and Drug Administration, Silver Spring, MD. Available from: http://www. accessdata.fda.gov/ drugsatfda-docs/label/2010/021366s021lbl.pdf [Last accessed: May 27, 2011]
15. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr (2009) Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality and all-cause mortality in older U.S. adults. J Am Geriatr Soc 57(9): 1595-603
16. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study Arch Intern Med 168(11): 1174-80 (Pubitemid 351831400)
17. Glynn RJ, Danielson E, Fonseca FA et al (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360(18): 1851-61
18. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM (2010) Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152(8): 488-96
19. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GKW, Wassef M, Dzau VJ (2005) Atherosclerosis 2005: Recent discoveries and novel hypotheses. Circulation 112(21): 3348-53 (Pubitemid 43739381)
20. Grimes DS, Hindle E, Dyer T (1996) Sunlight, cholesterol and coronary heart disease. QJM 89(8): 579-89 (Pubitemid 26278869)
21. Grimes DS (2006) Are statins analogues of vitamin D?. Lancet 368(9529): 83-6 (Pubitemid 43947207)
22. Hirschfield GM, Pepys MB, (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96(11): 793-807 (Pubitemid 37369294)
23. Lakka TA, Lakka HM, Rankinen T et al (2005) Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study Eur Heart J 26(19): 2018-25 (Pubitemid 41435729)
24. Li L, Roumeliotis N, Sawamura T, Renier G (2004) C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95(9): 877-83 (Pubitemid 39435002)
25. Lindqvist PG, Epstein E, Olsson H (2009) Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 7(4): 605-10
26. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4): 459-67 (Pubitemid 46184197)
27. Mikirova NA, Belcaro G, Jackson JA, Riordan NH (2010) Vitamin D concentrations, endothelial progenitor cells, and cardiovascular risk factors. Panminerva Med 52(2 Suppl 1): 81-7
28. Mora S, Cook N, Buring JE, Ridker PM, Lee IM (2007) Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 116(19): 2110-8 (Pubitemid 350060348)
29. Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, Ridker PM (2010) Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials. Circulation 121(9): 1069-77
30. Nursing and Midwifery Council (2007) Standards for Medicines Management. NMC, London
31. Nursing and Midwifery Council (2008) The Code: Standards of Conduct, Performance and Ethics for Nurses and Midwives. NMC, London.
32. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R, (2000) 1α,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 102(23): 2867-72
33. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3): 499-511 (Pubitemid 36158056)
34. Pérez-Castrillón JL, Vega G, Abad L et al (2007) Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99(7): 903-5 (Pubitemid 46483276)
35. Pilz S, Dobnig H, Fischer JE et al (2008) Low vitamin D levels predict stroke in patients referred to coronary angiography Stroke 39(9): 2611-3
36. Ridker PM, Rifai N, Rose L, Buring, JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20): 1557-65 (Pubitemid 35315836)
37. Ridker PM, Cook N (2004) Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109(16): 1955-9 (Pubitemid 38544485)
38. Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy N Engl J Med 352(1): 20-8 (Pubitemid 40075677)
39. Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6): 611-9
40. Ridker PM, Danielson MIA, Fonseca FAH et al (2008a) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21): 2195-207
41. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008b) C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118(22): 2243-51
42. Rdker PM, Danielson E, Fonseca FA et al (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373(9670): 1175-82
43. Ridker PM, Macfadyen J, Cressman M, Glynn RJ (2010a) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) Trial. J Am Coll Cardiol 55(12): 1266-73
44. Ridker PM, MacFadyen J, Libby P, Glynn RJ (2010b) Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 106(2): 204-9
45. Spiel AO, Mayr FB, Leitner JM, Firbas C, Sieghart W, Jilma B (2008) Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 123(1): 108-13
46. Targher G, Bertolini L, Padovani R et al (2006). Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol 65(5): 593-7 (Pubitemid 44583818)
47. Vasa M, Fichtlscherer S, Adler K et al (2001) Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103(24): 2885-90 (Pubitemid 32578123)
48. Verma S, Kuliszewski MA, Li SH et al (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109(17): 2058-67 (Pubitemid 38620212)
49. Volanakis JE (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol 38(2-3):189-97 (Pubitemid 32786776)
50. Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4): 503-11
51. Yavuz B, Ertugrul DT, Cil H et al (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23 (4): 295-9